STAGNATIONS AND REGRESSIONS IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS

Tullio Bertani; Giuseppe Remuzzi

doi:10.1016/s0140-6736(83)90071-5

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2013

Prevalence of C3 mutations in primary membranoproliferative glomerulonephritis

Elisabetta Valoti, Elena Bresin, Rossella Piras, Marta Alberti, Annalisa Sorosina, Roberta Donadelli, Giuseppe Remuzzi, Marina Noris

Article2021

Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment

Marina Noris, Erica Daina, Giuseppe Remuzzi

Article2024

Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Andrew S. Bomback, Erica Daina, Giuseppe Remuzzi, John Kanellis, David Kavanagh, Matthew C. Pickering, Gere Sunder‐Plassmann, Patrick D. Walker, Zhongshen Wang, Zurish Ahmad, Fádi Fakhouri

Article2018

The Role of Thymic Stromal Lymphopoietin (TSLP) in Glomerulonephritis

Keum Hwa Lee, Jae Won Yang, Jin Young Cho, Eun‐Kyung Lim, Michael Eisenhut, Dong Yeon Jeong, Johanna Steingroever, Jae Il Shin

Article2023

Functional Magnetic Resonance Imaging to Monitor Disease Progression: A Prospective Study in Patients with Primary Membranoproliferative Glomerulonephritis

Giulia Villa, Erica Daina, Paolo Brambilla, Sara Gamba, Valentina Fanny Leone, Camillo Carrara, Paola Rizzo, Marina Noris, Giuseppe Remuzzi, Andrea Remuzzi, Anna Caroli